Introductiom
============

Serous cystadenoma (SCA) is fundamentally a multilobular cystic tumor that consists of a thin capsule and small cysts only millimeters in diameter. SCA constitutes approximately only 1 to 2% of all pancreatic tumors ([@b1-mco-0-0-1598]), but the number of patients with SCA has been growing due to the frequent use of radiography and recent improvements of imaging modalities. SCA is currently categorized into four subtypes: microcystic, macrocystic, mixed, and solid types. The most common subtype is microcystic type, and the cystic structure can be easily recognized in the former three subtypes. On the other hand, the solid type accounts for only 3% of all SCAs in a Japanese multicenter study ([@b1-mco-0-0-1598]), and it is described as noncystic, meaning that a cystic structure is too tiny to be detected macroscopically. Solid SCA is usually misdiagnosed preoperatively as neuroendocrine tumor (NET) ([@b2-mco-0-0-1598]). In several case reports, the authors reported that magnetic resonance cholangiopancreatography (MRCP) might be useful for preoperative diagnosis of SCA ([@b3-mco-0-0-1598]--[@b5-mco-0-0-1598]). However, it is generally considered difficult to preoperatively differentiate SCA from other solid pancreatic tumors by imaging modalities.

The present report describes a rare case of solid SCA in which the magnetic resonance imaging (MRI) findings were very informative in the diagnosis and decision to perform middle segment pancreatectomy as an organ-preserving surgical strategy.

Case report
===========

A 50-year-old woman was referred to the Department of Surgery in Osaka University Hospital for investigation of a pancreatic body mass detected during a health examination. She had no chief complaint. A benign thyroid tumor had been found, and she was followed up by annual ultrasonography. Physical examination revealed normal abdominal findings. Laboratory examination revealed no anemia, jaundice, or hyperglycemia. The serum level of carcinoembryonic antigen and carbohydrate antigen 19-9 were within the reference ranges, and no excess of pancreatic endocrine hormones, including insulin, glucagon, and gastrin, was observed.

Contrast-enhanced computed tomography (CT) demonstrated a 2-cm solid mass in the body of the pancreas, which was strongly enhanced in the early phase ([Fig. 1A](#f1-mco-0-0-1598){ref-type="fig"}). Fluorine-18 fluorodeoxyglucose positron emission tomography-CT showed no abnormal accumulation of the tracer in the tumor ([Fig. 1B](#f1-mco-0-0-1598){ref-type="fig"}). Endoscopic ultrasonography (EUS) revealed a hypoechoic, heterogeneous, and hypervascular solid mass without posterior echo enhancement in the body of the pancreas, and no cystic component could be recognized ([Fig. 1C and D](#f1-mco-0-0-1598){ref-type="fig"}). We performed EUS-guided fine needle aspiration (FNA) three times, but could not obtain adequate specimens for diagnosis because of contamination of blood. MRI clearly showed a round mass with low intensity on T1-weighted images ([Fig. 2A](#f2-mco-0-0-1598){ref-type="fig"}) and high intensity on both T2-weighted images ([Fig.2B](#f2-mco-0-0-1598){ref-type="fig"}) and diffusion-weighted images ([Fig. 2C](#f2-mco-0-0-1598){ref-type="fig"}). MRCP showed high intensity, and the tumor signal intensity was similar to that of an incidentally detected hepatic cyst ([Fig. 2D](#f2-mco-0-0-1598){ref-type="fig"}). We strongly suspected the tumor to be a solid SCA based on the radiological findings, including MRCP, but histological confirmation could not be gained. We finally performed middle segment pancreatectomy as a function-preserving surgery. The resected specimen was 2.6 cm in width, and surgical margin was ascertained by intraoperative ultrasonography ([Fig. 3A](#f3-mco-0-0-1598){ref-type="fig"}). The cranial stump was cut off using a triple-row linear stapler and caudal stump was reconstructed by pancreaticogastrostomy using mattress sutures ([@b6-mco-0-0-1598]). The patient\'s recovery was complicated by pulmonary embolism (Grade 3 by Common Terminology Criteria for Adverse Events: CTCAE) and pancreatic fistula (Grade B by International Study Group of Pancreatic Fistula classification: ISGPF). The patient recovered with conservative treatment for pancreatic fistula and anti-coagulation therapy with warfarin for pulmonary embolism, and she was discharged on the 49 postoperative day.

The pancreatic tumor was clearly circumscribed within the resected specimen, and the cut surface of the tumor was solid, glossy, and reddish with a central fibrous scar in a stellate pattern ([Fig. 3B](#f3-mco-0-0-1598){ref-type="fig"}). It was 2.2 cm in size, and no honeycomb structure characteristic of small cysts was detected macroscopically. Formalin-fixed paraffin-embedded tissue sections were prepared, and immunohistochemical staining was conducted using following antibodies; anti-mucin 6 antibody (Leica Biosystems, Nussloch, Germany), anti-synaptophysin antibody, anti-chromogranin antibody (both from Dako, Glostrup, Denmark) and anti-Ki-67 antibody (Roche Diagnostics, Basel, Switzerland). Briefly, the sections were incubated at room temperature with anti-mucin 6 for 32 min, anti-synaptophysin for 16 min, anti-chromogranin A for 16 min and anti-Ki-67 for 16 min, respectively. Microscopic examination revealed numerous microcysts separated by hypocellular and dense collagen fibers. The inner surface of the cysts was lined by a single layer of cuboidal epithelium with clear cytoplasm ([Fig. 4A](#f4-mco-0-0-1598){ref-type="fig"}). The cytoplasm was strongly stained by periodic acid-Schiff and digested by diastase because of the presence of abundant intracytoplasmic glycogen ([Fig. 4B and C](#f4-mco-0-0-1598){ref-type="fig"}). The tumor cells were positive for mucin 6 ([Fig. 4D](#f4-mco-0-0-1598){ref-type="fig"}) and negative for neuroendocrine differentiation labeling (synaptophysin ([Fig. 4E](#f4-mco-0-0-1598){ref-type="fig"}) or chromogranin A ([Fig. 4F](#f4-mco-0-0-1598){ref-type="fig"}). The Ki-67 labeling index was 1 to 2%, and there was no evidence of malignancy or lymph node metastasis. The final diagnosis was a solid SCA. She had been in follow-up by every three months laboratory check and every six months radiological check by CT. At the time of this writing (1 year postoperatively), the patient was clinically well with no evidence of recurrence. She had no diarrhea and weight loss without digestive enzymes. In addition, she also maintained favorable glucose tolerance without oral hypoglycemic agents or insulin. The preoperative and postoperative hemoglobin A1c level was not worsened (5.8 and 6.0%, respectively). This clinical research was approved by the Research Ethics Board of the Osaka University Research Committee and conducted according to Institutional Review Board guidelines. Written informed consent was obtained from the patient prior to publication of the present case report.

Discussion
==========

In 1978, Compagno and Oertel ([@b7-mco-0-0-1598]) first proposed the concept of serous cystic neoplasm of the pancreas. SCA is morphologically classified into four subtypes: microcystic, macrocystic, mixed, and solid types. The solid variant of SCA was first described by Perez-Ordonez *et al* ([@b8-mco-0-0-1598]) in 1996, who reported that the cells were arranged in small acini with no or minute central lumina, resembling a solid tumor. The characteristic radiological findings of SCA, such as a honeycomb appearance, polycystic pattern, lobularity, sunburst appearance (central calcification), and hemorrhage, are quite rare in solid SCA. Solid SCA is so rare that the incidence is only 3.0% of all SCAs, compared with microcystic type (58%) and macrocystic type (20%) ([@b1-mco-0-0-1598]). Whether solid SCA is a variant of SCA or a separate disease entity was historically controversial ([@b5-mco-0-0-1598],[@b8-mco-0-0-1598],[@b9-mco-0-0-1598]), but it is now considered a variant of SCA because the cytological and immunohistological features of this tumor are very similar to those of SCA. Compared with the microcystic type, which is composed of numerous tiny cysts (usually \~2--10 mm), the solid type is formed by far smaller cysts that cannot be recognized by the naked eye and shows a homogeneous and glossy appearance.

We systematically reviewed the English literature by using PubMed and Google Scholar from 1995 to 2017. The keywords of 'solid serous cystadenoma', 'solid-type serous cystadenoma', 'serous cystic neoplasm' or 'solid serous adenoma' were used. We excluded the nonsurgical cases. To our knowledge, only 19 cases including our case have been published with a pathological confirmation ([Table I](#tI-mco-0-0-1598){ref-type="table"}) ([@b2-mco-0-0-1598],[@b3-mco-0-0-1598],[@b5-mco-0-0-1598],[@b8-mco-0-0-1598]--[@b19-mco-0-0-1598]).

Some reports have described the radiological findings of solid SCA. A honeycomb structure is generally a typical finding of SCA; however, this finding cannot be detected in solid SCA even by EUS because the internal microlevel structure is difficult to capture. As a result, solid SCA is difficult to distinguish from other solid pancreatic tumors such as NET, acinar cell carcinoma, solid pseudopapillary tumor, and metastatic carcinoma. In most cases, NET is an especially important differential diagnosis because it is clinically the most common hypervascular solid tumor of the pancreas. Several case reports have shown that MRCP is a useful tool in distinguishing solid SCA from other solid pancreatic tumors ([@b3-mco-0-0-1598]--[@b5-mco-0-0-1598]). Solid SCA is reported to show T1 low intensity and T2 high intensity almost same as the other types of SCA ([@b1-mco-0-0-1598]). In general, MRCP involves heavily T2-weighted sequences, and the echo time is prolonged to about 10 times longer than regular T2-weighted imaging. On MRCP images, only a pure water cyst can gain hyperintensity. Both solid SCA and NET generally show hyperintensity on regular T2-weighted images. However, only solid SCA maintains this high intensity because of its cystic nature on MRCP. The high intensity on MRCP is quite a useful clue for clearly differentiating solid SCA from NET. MRI is becoming as common as CT for diagnostic modality. It can provide large amounts of valuable anatomical information preoperatively ([@b20-mco-0-0-1598]--[@b22-mco-0-0-1598]). If a tumor reveals high intensity on MRCP, this indicates that the tumor is composed mainly of not a solid substance but rather a watery fluid. In the present case, the signal intensity of the tumor was similar to that of the incidentally detected hepatic cyst. This finding could also be valuable for reaching the accurate preoperative diagnosis.

With respect to treatment, expectant management has been proposed when SCA is small and definitely diagnosed because this neoplasm grows slowly and there is a minimal risk of malignant transformation ([@b23-mco-0-0-1598]). When nonoperative management is selected, histological examination by EUS-FNA is recommended to provide essential information in advance, but an adequate specimen can be rarely obtained by EUS-FNA.

The role of EUS-FNA is to obtain preoperative cytological confirmation of pancreatic malignant tumors ([@b24-mco-0-0-1598]), and tumor markers and DNA analysis of cyst aspirates are reportedly helpful in improving diagnostic yield ([@b25-mco-0-0-1598]). EUS-FNA is recommended for NET as an informative tool in differentiating from other pancreatic tumors because of its high diagnostic sensitivity, which is reported as high as 87--90% ([@b26-mco-0-0-1598]--[@b28-mco-0-0-1598]). However, the reported diagnostic accuracy of EUS-guided biopsy for cystic tumors of the pancreas ranges from 17--21% ([@b18-mco-0-0-1598],[@b29-mco-0-0-1598]--[@b31-mco-0-0-1598]), and the specimen often lacks the epithelial tissue necessary for diagnosis because of its cystic nature. Consequently, EUS-FNA alone is unlikely to provide the high level of diagnostic evidence necessary to support observational management. The indication for EUS about solid SCA is not mentioned because of its rarity in the guidelines about pancreatic cysts ([@b25-mco-0-0-1598],[@b32-mco-0-0-1598]--[@b34-mco-0-0-1598]). In the present case, the tumor was initially deemed a NET because of its hypervascularity and solid appearance. However, the MRCP finding strongly indicated the possibility of solid SCA. We tried to gain histological confirmation by EUS-FNA, but ended up as a failure, and the possibility of NET could not be excluded. We finally selected surgical intervention because solid SCA is rare and the final diagnosis ought to be based on histological confirmation of a surgical specimen unless the diagnosis is preoperatively assured by EUS-FNA.

We performed middle segment pancreatectomy as a function-preserving surgery because the tumor was as small as 2.2 cm. An organ-preserving surgical procedure is generally recommended for SCA because lymph node metastasis of SCA is quite rare and lymphadenectomy is not necessary ([@b35-mco-0-0-1598]). In previous reports of SCA with clear mention about operative procedure, all of the 13 patients underwent pancreaticoduodenectomy, distal pancreatectomy, or enucleation ([Table I](#tI-mco-0-0-1598){ref-type="table"}). Previous five cases lacked in operation method, as those reports placed value in the imaging pitfalls of solid SCA. Therefore, Our case is the first in which middle segment pancreatectomy was performed for a solid SCA as an organ-preserving surgery, and this procedure might lead to better preservation of endocrine function ([@b36-mco-0-0-1598]).

Solid SCA of the pancreas is definitively a rare disease, but oncologic surgeons should be aware of the characteristics of this neoplasm to allow for a correct preoperative diagnosis. Further investigation to accumulate more evidence regarding this rare disease is expected.

We experienced a case of solid SCA of the pancreas for which MRCP imaging was very helpful for accurate diagnosis and decision-making regarding the surgical method.
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![Computed tomography (CT) and abdominal ultrasonography. (A) Contrast-enhanced CT showed a well-enhanced solid tumor of 2 cm in the body of pancreas (arrow). (B) Positron emission tomography--CT showed no abnormal uptake (arrow). (C and D) Endoscopic ultrasonography showed a well circumscribed, hypoechoic, and hypervascular tumor without posterior echo enhancement.](mco-08-05-0675-g00){#f1-mco-0-0-1598}

![Magnetic resonance imaging. (A) low intensity on T1-weighted imaging (arrow), (B) high intensity on T2-weighted imaging (arrow), and (C) high intensity on diffusion-weighted imaging (arrow). (D) On a coronal magnetic resonance cholangiopancreatography image, the tumor showed high intensity (arrow), which was similar to that of the incidentally detected hepatic cyst (arrowhead).](mco-08-05-0675-g01){#f2-mco-0-0-1598}

![Resected specimen of the tumor. (A) Middle segment pancreatectomy was performed with enough surgical margin. (B) Macroscopic photograph of the pancreatic resection specimen, revealing a solid and glossy appearance with central fibrous tissue. The tumor measured 2.2 cm.](mco-08-05-0675-g02){#f3-mco-0-0-1598}

![Histological examination of the resected specimen. (A) Microscopically, the tumor was composed of numerous tiny cysts lined by a single layer of cuboidal epithelium with abundant fibrous stroma (hematoxylin and eosin stain, ×400). (B) The cytoplasm was strongly stained by periodic acid-Schiff stain (×400) and (C) digested by diastase (×400). The cells were positive for (D) mucin 6 (×400) and negative for (E) synaptophysin (×200) and (F) chromogranin A (×200).](mco-08-05-0675-g03){#f4-mco-0-0-1598}

###### 

Literature review of the clinicopathological findings of patients with solid-type serous cystadenomas.

  No.   Authors                 Year   Age (years)   Sex   Symptoms                Location   Size (cm)   Enhancement   MRI (T1/T2/MRCP)     Clinical diagnosis                                          Operation         (Refs.)
  ----- ----------------------- ------ ------------- ----- ----------------------- ---------- ----------- ------------- -------------------- ----------------------------------------------------------- ----------------- -----------------------
  1     Perez-Ordonez *et al*   1996   70            F     Abdominal Pain          Pt         4.0         −             −                    NET                                                         DP                ([@b8-mco-0-0-1598])
  2     Kosmahl *et al*         2004   50            M     −                       Ph         2.5         −             −                    −                                                           PPPD              ([@b10-mco-0-0-1598])
  3     Yamamoto *et al*        2004   60            M     Epigastric distention   Ph         2.0         Yes           Low/high/high        NET                                                         PPPD              ([@b5-mco-0-0-1598])
  4     Gabata *et al*          2005   59            F     Abdominal Pain          Pb         2.0         Yes           Low/high/high        Solid SCA                                                   DP                ([@b3-mco-0-0-1598])
  5     Yamaguchi               2006   58            F     None                    Pb         2.0         Yes           −                    NET                                                         DP                ([@b9-mco-0-0-1598])
  6     Reese *et al*           2006   66            M     None                    Ph         4.0         Yes           −                    NET                                                         PPPD              ([@b11-mco-0-0-1598])
  7     Sanaka *et al*          2007   74            M     None                    Pb         1.6         Yes           −                    NET                                                         Enucleation       ([@b12-mco-0-0-1598])
  8     Stern *et al*           2007   62            M     Abdominal Pain          Pbh        4.2         −             −                    NET, others^[a](#tfn1-mco-0-0-1598){ref-type="table-fn"}^   DP                ([@b13-mco-0-0-1598])
  9     Casadei *et al*         2008   59            F     Abdominal Pain          Pt         4.0         Yes           −                    Solid SCA                                                   DP                ([@b14-mco-0-0-1598])
  10    Yasuda *et al*          2009   72            F     None                    Ph         1.7         Yes           −/high/−             NET                                                         PPPD              ([@b15-mco-0-0-1598])
  11    Hayashi *et al*         2012   74            F     −                       Pb         4.2         Yes           −                    −                                                           −                 ([@b16-mco-0-0-1598])
  12    Hayashi *et al*         2012   57            F     −                       Ph         2.1         Yes           −                    −                                                           −                 ([@b16-mco-0-0-1598])
  13    Hayashi *et al*         2012   58            F     −                       Pb         3.2         Yes           −                    −                                                           −                 ([@b16-mco-0-0-1598])
  14    Lee *et al*             2013   56            M     None                    Pt         2.5         Yes           −                    NET                                                         Laparoscopic DP   ([@b17-mco-0-0-1598])
  15    Kishida *et al*         2013   58            M     None                    Pb         2.8         Yes           Low/high/high        NET                                                         DP                ([@b18-mco-0-0-1598])
  16    Ishigami *et al*        2014   43            F     −                       Ph         −           Yes           Low/−/Not detected   −                                                           −                 ([@b19-mco-0-0-1598])
  17    Ishigami *et al*        2014   65            F     −                       Ptb        −           Yes           −/−/Not detected     −                                                           −                 ([@b19-mco-0-0-1598])
  18    Katsourakis *et al*     2016   72            F     Abdominal Pain          Pt         3.0         Yes           −/−                  NET                                                         DP                ([@b2-mco-0-0-1598])
  19    Present case                   50            F     None                    Pb         2.2         Yes           Low/high/high        Solid SCA                                                   MP                

Others include pancreatic ductal adenocarcinoma, solid pseudopapillary tumor, and metastatic carcinoma; DP, distal pancreatectomy; F, female; M, male; MP, middle segment pancreatectomy; MRI, magnetic resonance imaging; NET, neuroendocrine tumor; Pb, pancreas body; Ph, pancreas head; Pt, pancreatic tail; PPPD, pylorus preserving pancreaticoduodenectomy; SCA, serous cystadenoma.
